{"id":15558,"date":"2018-05-28T18:09:41","date_gmt":"2018-05-28T18:09:41","guid":{"rendered":"https:\/\/mann.vamtam.com\/?page_id=15558"},"modified":"2021-11-25T22:09:00","modified_gmt":"2021-11-25T22:09:00","slug":"agenda","status":"publish","type":"page","link":"https:\/\/www.biotechpharmasummit.com\/index.php\/agenda\/","title":{"rendered":"Agenda"},"content":{"rendered":"
\n\n\t\t

Download now the Official In-Person Agenda<\/h3>\n\t\n\t\t\t\t\tClick here to download the agenda\n\t<\/a>\n\n\t\t\t\t\n\t

Agenda for the Virtual Format of the conference<\/h2>\n

Please note: The agenda below is only for the virtual format.<\/strong><\/p>\n\t\t\t1. Antibody Engineering & Therapeutics\t\t\n\t\t\t2. Inhalation & Respiratory Drug Delivery\t\t\n\t\t\t3. Pharmacovigilance & Drug Safety\t\t\n\t\t\t4. Pre-filled Syringes & Injectables\t\t\n\t\t\t5. Gut-Brain Axis\t\t\n\t\t\t6. Probiotics, Human & Skin Microbiome\t\t\n\t\t\t7. Aseptic Processing Technology\t\t\n\t\t\t8. CDx\/Biomarkers & Biobanking\t\t\n\t\t\t\t

\n\t
\n\t\t\t\t\t\t
\n\t\t\n
\n\t\t\t
\n\t
\n\t
\n\t\t

\n\t\t\t<\/span>\n\t\n\t\n\tDay 1<\/span>\n\n\t\n\t\t\t<\/span>\n\t<\/h3>\n\t<\/div>\n<\/div>\n<\/div>\n<\/div>\n\t\t\t
\n\t
\n\t
\n\t\t

\n\t\t\t<\/span>\n\t\n\t\n\tDay 2<\/span>\n\n\t\n\t\t\t<\/span>\n\t<\/h3>\n\t<\/div>\n<\/div>\n<\/div>\n<\/div>\n\t<\/div>\n\n
\n\t\t\t
\n\t
\n\t
\n\t\t
\n\t\n\t\n\tDay 1 | 08:00<\/span>\n\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\t\t<\/span>\n\t\n\t\t\t\n\t\n\tAntibody Manufacturing Strategies during a Pandemic<\/span>\n\n\t\t\t<\/a>\n\t\n\t\t\t<\/span>\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\n\t\t\t\n\t\n\tNick Hutchinson, Business Steering Group Lead for Mammalian Cell Culture Services at FUJIFILM Diosynth Biotechnologies<\/span>\n\n\t\t\t<\/a>\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n<\/div>\n<\/div>\n\t\t\t
\n\t
\n\t
\n\t\t
\n\t\n\t\n\tDay 2 | 08:00<\/span>\n\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\t\t<\/span>\n\t\n\t\t\t\n\t\n\tFully human antibody discovery strategy<\/span>\n\n\t\t\t<\/a>\n\t\n\t\t\t<\/span>\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\n\t\t\t\n\t\n\tLi Chen, Director of Biologics Discovery at GenScript ProBio<\/span>\n\n\t\t\t<\/a>\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n<\/div>\n<\/div>\n\t<\/div>\n\t\t<\/div>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t\t\t\t\t
\n\t\t\n
\n\t\t\t
\n\t
\n\t
\n\t\t
\n\t\n\t\n\tDay 1 | 09:00<\/span>\n\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\t\t<\/span>\n\t\n\t\t\t\n\t\n\tLessons in Discovering Antibodies against GPCRs, Ion Channels, and Transporters<\/span>\n\n\t\t\t<\/a>\n\t\n\t\t\t<\/span>\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\n\t\t\t\n\t\n\tBenjamin Doranz, PhD, MBA President & CEO at Integral Molecular<\/span>\n\n\t\t\t<\/a>\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n<\/div>\n<\/div>\n\t\t\t
\n\t
\n\t
\n\t\t
\n\t\n\t\n\tDay 2 | 09:00<\/span>\n\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\t\t<\/span>\n\t\n\t\t\t\n\t\n\tTopic to be announced<\/span>\n\n\t\t\t<\/a>\n\t\n\t\t\t<\/span>\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\n\t\t\t\n\t\n\tVu Truong, Ph.D. Founder, Chief Executive Officer, and Director at Aridis Pharmaceuticals, Inc.<\/span>\n\n\t\t\t<\/a>\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n<\/div>\n<\/div>\n\t<\/div>\n\t\t<\/div>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t\t\t\t\t
\n\t\t\n
\n\t\t\t
\n\t
\n\t
\n\t\t
\n\t\n\t\n\tDay 1 | 10:00<\/span>\n\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\t\t<\/span>\n\t\n\t\t\t\n\t\n\tHeavy Chain Only Antibodies to SARS-CoV-2<\/span>\n\n\t\t\t<\/a>\n\t\n\t\t\t<\/span>\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\n\t\t\t\n\t\n\tDr. Philip Leighton, Sr. Director, Molecular Biology at Ligand Pharmaceuticals Incorporated<\/span>\n\n\t\t\t<\/a>\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n<\/div>\n<\/div>\n\t\t\t
\n\t
\n\t
\n\t\t
\n\t\n\t\n\tDay 2 | 10:00<\/span>\n\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\t\t<\/span>\n\t\n\t\t\t\n\t\n\tSingle-chain TNFSF ligands as building blocks for costimulatory bispecifics<\/span>\n\n\t\t\t<\/a>\n\t\n\t\t\t<\/span>\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\n\t\t\t\n\t\n\tDr. Katharina Billian-Frey, Head of Protein Engineering at Apogenix AG<\/span>\n\n\t\t\t<\/a>\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n<\/div>\n<\/div>\n\t<\/div>\n\t\t<\/div>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t\t\t\t\t
\n\t\t\n
\n\t\t\t
\n\t
\n\t
\n\t\t
\n\t\n\t\n\tDay 1 | 11:00<\/span>\n\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\t\t<\/span>\n\t\n\t\t\t\n\t\n\tTaking antibody candidate generation from the lab to the cloud with de novo computational design <\/span>\n\n\t\t\t<\/a>\n\t\n\t\t\t<\/span>\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\n\t\t\t\n\t\n\tMonica Berrondo, CEO at Macromoltek<\/span>\n\n\t\t\t<\/a>\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n<\/div>\n<\/div>\n\t\t\t
\n\t
\n\t
\n\t\t
\n\t\n\t\n\tDay 2 | 11:00<\/span>\n\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\t\t<\/span>\n\t\n\t\t\t\n\t\n\tThe art of making multifunctional antibodies: therapeutic opportunities and technical challenges<\/span>\n\n\t\t\t<\/a>\n\t\n\t\t\t<\/span>\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\n\t\t\t\n\t\n\tHarald Kolmar, Ph.D. Department Head and Professor of Applied Biochemistry at Technical University of Darmstadt<\/span>\n\n\t\t\t<\/a>\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n<\/div>\n<\/div>\n\t<\/div>\n\t\t<\/div>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t\t\t\t\t
\n\t\t\n
\n\t\t\t
\n\t
\n\t
\n\t\t
\n\t\n\t\n\tDay 1 | 12:00<\/span>\n\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\t\t<\/span>\n\t\n\t\t\t\n\t\n\tAntibiotic Discovery by Means of Computers<\/span>\n\n\t\t\t<\/a>\n\t\n\t\t\t<\/span>\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\n\t\t\t\n\t\n\tC\u00e9sar de la Fuente, Ph.D. Presidential Assistant Professor at UPenn<\/span>\n\n\t\t\t<\/a>\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n<\/div>\n<\/div>\n\t\t\t
\n\t
\n\t
\n\t\t
\n\t\n\t\n\tDay 2 | 12:00<\/span>\n\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\t\t<\/span>\n\t\n\t\t\t\n\t\n\tChallenges in characterization and developability of multispecific antibodies<\/span>\n\n\t\t\t<\/a>\n\t\n\t\t\t<\/span>\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\n\t\t\t\n\t\n\tSoraya H\u00f6lper, PhD Lab Head Mass Spectrometry at Sanofi<\/span>\n\n\t\t\t<\/a>\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n<\/div>\n<\/div>\n\t<\/div>\n\t\t<\/div>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t\t\t\t\t
\n\t\t\n
\n\t\t\t
\n\t
\n\t
\n\t\t
\n\t\n\t\n\tDay 1 | 13:00<\/span>\n\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\t\t<\/span>\n\t\n\t\t\t\n\t\n\tDesigning and Developing Next-Generation Antibody-Drug Conjugate Medicines<\/span>\n\n\t\t\t<\/a>\n\t\n\t\t\t<\/span>\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\n\t\t\t\n\t\n\tNicolas Camper, Group Leader, Bioconjugation Chemistry at Abzena<\/span>\n\n\t\t\t<\/a>\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n<\/div>\n<\/div>\n\t\t\t
\n\t
\n\t
\n\t\t
\n\t\n\t\n\tDay 2 | 13:00<\/span>\n\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\t\t<\/span>\n\t\n\t\t\t\n\t\n\tLeap In Transposase Platform: From shiny and new to tried and true<\/span>\n\n\t\t\t<\/a>\n\t\n\t\t\t<\/span>\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\n\t\t\t\n\t\n\tOren Beske, Ph.D. Amalgamator of Business and Biology at ATUM<\/span>\n\n\t\t\t<\/a>\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n<\/div>\n<\/div>\n\t<\/div>\n\t\t<\/div>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t\t\t\t\t
\n\t\t\n
\n\t\t\t
\n\t
\n\t
\n\t\t
\n\t\n\t\n\tDay 1 | 14:00<\/span>\n\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\t\t<\/span>\n\t\n\t\t\t\n\t\n\tNovel Solution For High Throughput Antibody And Protein Purification Using Magnetic Beads.<\/span>\n\n\t\t\t<\/a>\n\t\n\t\t\t<\/span>\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\n\t\t\t\n\t\n\tNishant Saxena, Ph.D. Product Manager, Protein Purification at GenScript USA Inc.<\/span>\n\n\t\t\t<\/a>\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n<\/div>\n<\/div>\n\t\t\t
\n\t
\n\t
\n\t\t
\n\t\n\t\n\tDay 2 | 14:00<\/span>\n\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\t\t<\/span>\n\t\n\t\t\t\n\t\n\tAffinity maturation of B7-H6 translates into enhanced NK cell-mediated tumor cell lysis and improved proinflammatory cytokine release of bispecific immunoligands via NKp30 engagement<\/span>\n\n\t\t\t<\/a>\n\t\n\t\t\t<\/span>\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\n\t\n\tStefan Zielonka, Associate Director at Merck KGaA<\/span>\n\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n<\/div>\n<\/div>\n\t<\/div>\n\t\t<\/div>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t\t\t\t\t
\n\t\t\n
\n\t\t\t
\n\t
\n\t
\n\t\t
\n\t\n\t\n\tDay 1 | 15:00<\/span>\n\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\t\t<\/span>\n\t\n\t\t\t\n\t\n\tDiscovery and engineering of Immuno-oncology antibodies \u2013 Effective formats and impactful combinations<\/span>\n\n\t\t\t<\/a>\n\t\n\t\t\t<\/span>\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\n\t\t\t\n\t\n\tMarc A. van Dijk, Chief Technology Officer at Agenus Inc<\/span>\n\n\t\t\t<\/a>\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n<\/div>\n<\/div>\n\t\t\t
\n\t
\n\t
\n\t\t
\n\t\n\t\n\tDay 2 | 15:00<\/span>\n\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\t\t<\/span>\n\t\n\t\t\t\n\t\n\tBuilding a Biotechnology Ecosystem.<\/span>\n\n\t\t\t<\/a>\n\t\n\t\t\t<\/span>\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\n\t\t\t\n\t\n\tHeather Schwoebel, Senior Vice President of BD, Head of Platform Licensing at Alloy Therapeutics, Inc.<\/span>\n\n\t\t\t<\/a>\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n<\/div>\n<\/div>\n\t<\/div>\n\t\t<\/div>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t\t\t\t\t
\n\t\t\n
\n\t\t\t
\n\t
\n\t
\n\t\t
\n\t\n\t\n\tDay 1 | 16:00<\/span>\n\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\t\t<\/span>\n\t\n\t\t\t\n\t\n\tFunneling while maintaining diversity: strategies for therapeutic antibody campaigns<\/span>\n\n\t\t\t<\/a>\n\t\n\t\t\t<\/span>\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\n\t\t\t\n\t\n\tIlse Roodink, Chief Scientific Officer at ImmunoPrecise Antibodies<\/span>\n\n\t\t\t<\/a>\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n<\/div>\n<\/div>\n\t\t\t
\n\t
\n\t
\n\t\t
\n\t\n\t\n\tDay 2 | 16:00<\/span>\n\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\t\t<\/span>\n\t\n\t\t\t\n\t\n\tBispecific \u03b3\u03b4-T cell engagers for the treatment of cancer<\/span>\n\n\t\t\t<\/a>\n\t\n\t\t\t<\/span>\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\n\t\t\t\n\t\n\tPaul W.H.I. Parren, PhD, Executive Vice President and Head of R&D at Lava Therapeutics<\/span>\n\n\t\t\t<\/a>\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n<\/div>\n<\/div>\n\t<\/div>\n\t\t<\/div>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t\t\t\t\t
\n\t\t\n
\n\t\t\t
\n\t
\n\t
\n\t\t
\n\t\n\t\n\tDay 1 | 17:00<\/span>\n\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\t\t<\/span>\n\t\n\t\t\t\n\t\n\tAntibody-targeted cytoplasmic delivery of fusion proteins and antibody fragments using Sapreme\u2019s endosomal escape enhancers<\/span>\n\n\t\t\t<\/a>\n\t\n\t\t\t<\/span>\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\n\t\t\t\n\t\n\tMiriam Bujny, Chief Development Officer (CDO) at Sapreme Technologies<\/span>\n\n\t\t\t<\/a>\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n<\/div>\n<\/div>\n\t\t\t
\n\t
\n\t
\n\t\t
\n\t\n\t\n\tDay 2 | 17:00<\/span>\n\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\t\t<\/span>\n\t\n\t\t\t\n\t\n\tNeo-X\u2019: A bispecific antibody concept targeting CD40 and tumor antigens to enhance neoantigen cross-presentation and T cell priming.<\/span>\n\n\t\t\t<\/a>\n\t\n\t\t\t<\/span>\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\n\t\t\t\n\t\n\tMattias Levin Sr Scientist, Antibody Engineering at Alligator Bioscience<\/span>\n\n\t\t\t<\/a>\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n<\/div>\n<\/div>\n\t<\/div>\n\t\t<\/div>\n\t<\/div>\n<\/div>\n<\/div>\t\t\t\n\t\t\t\t
\n\t
\n\t\t\t\t\t\t
\n\t\t\n
\n\t\t\t
\n\t
\n\t
\n\t\t

\n\t\t\t<\/span>\n\t\n\t\n\tDay 1<\/span>\n\n\t\n\t\t\t<\/span>\n\t<\/h3>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t

\n\t\t\t<\/span>\n\t\n\t\n\tPart I: The challenges of developing inhalation drugs<\/span>\n\n\t\n\t\t\t<\/span>\n\t<\/h4>\n\t<\/div>\n<\/div>\n<\/div>\n<\/div>\n\t\t\t
\n\t
\n\t
\n\t\t

\n\t\t\t<\/span>\n\t\n\t\n\tDay 2<\/span>\n\n\t\n\t\t\t<\/span>\n\t<\/h3>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t

\n\t\t\t<\/span>\n\t\n\t\n\tPart III: New Approaches to Treating Respiratory Diseases<\/span>\n\n\t\n\t\t\t<\/span>\n\t<\/h4>\n\t<\/div>\n<\/div>\n<\/div>\n<\/div>\n\t<\/div>\n\n
\n\t\t\t
\n\t
\n\t
\n\t\t
\n\t\n\t\n\tDay 1 | 09:00<\/span>\n\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\n\t\t\t\n\t\n\tBiologics Delivered in Liquid Form by Soft-Mist-Inhalers (SMI)<\/span>\n\n\t\t\t<\/a>\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\n\t\t\t\n\t\n\tBernhard M\u00fcllinger, General Manager, Chief Operating Officer at Resyca<\/span>\n\n\t\t\t<\/a>\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n<\/div>\n<\/div>\n\t\t\t
\n\t
\n\t
\n\t\t
\n\t\n\t\n\tDay 2 | 09:00<\/span>\n\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\t\t<\/span>\n\t\n\t\t\t\n\t\n\tUnmet Needs and Future Trends in Respiratory Drug Delivery<\/span>\n\n\t\t\t<\/a>\n\t\n\t\t\t<\/span>\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\n\t\t\t\n\t\n\tPaul Johnson, Managing Director at Paul Johnson Consulting Limited<\/span>\n\n\t\t\t<\/a>\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n<\/div>\n<\/div>\n\t<\/div>\n\t\t<\/div>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t\t\t\t\t
\n\t\t\n
\n\t\t\t
\n\t
\n\t
\n\t\t
\n\t\n\t\n\tDay 1 | 10:00<\/span>\n\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\t\t<\/span>\n\t\n\t\t\t\n\t\n\tShared Decision Making to Improve Adherence in Severe Asthma<\/span>\n\n\t\t\t<\/a>\n\t\n\t\t\t<\/span>\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\n\t\t\t\n\t\n\tTonya Winders, President and Chief Executive Officer at Allergy & Asthma Network<\/span>\n\n\t\t\t<\/a>\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n<\/div>\n<\/div>\n\t\t\t
\n\t
\n\t
\n\t\t
\n\t\n\t\n\tDay 2 | 10:00<\/span>\n\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\t\t<\/span>\n\t\n\t\t\t\n\t\n\tTowards development of patient-centric inhalers: Leveraging human factors, inhalation device and formulation science<\/span>\n\n\t\t\t<\/a>\n\t\n\t\t\t<\/span>\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\n\t\t\t\n\t\n\tN\u00e9lio Drumond, Senior Principal Scientist at Takeda Pharmaceuticals<\/span>\n\n\t\t\t<\/a>\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n<\/div>\n<\/div>\n\t<\/div>\n\t\t<\/div>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t\t\t\t\t
\n\t\t\n
\n\t\t\t
\n\t
\n\t
\n\t\t
\n\t\n\t\n\tDay 1 | 11:00<\/span>\n\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\t\t<\/span>\n\t\n\t\t\t\n\t\n\tIVIVC testing for OINDP products - Bridging the gap and accelerating product to market journey<\/span>\n\n\t\t\t<\/a>\n\t\n\t\t\t<\/span>\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\n\t\t\t\n\t\n\tAnna Sipitanou, Business Development Manager at Copley Scientific<\/span>\n\n\t\t\t<\/a>\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n<\/div>\n<\/div>\n\t\t\t
\n\t
\n\t
\n\t\t
\n\t\n\t\n\tDay 2 | 11:00<\/span>\n\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\t\t<\/span>\n\t\n\t\t\t\n\t\n\tAre Sustainability, Reusability and Carbon Neutrality Major Trends for Devices in the Future?<\/span>\n\n\t\t\t<\/a>\n\t\n\t\t\t<\/span>\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\n\t\t\t\n\t\n\tFelix Weiland, Head of Product & Process Technology at Boehringer Ingelheim<\/span>\n\n\t\t\t<\/a>\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n<\/div>\n<\/div>\n\t<\/div>\n\t\t<\/div>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t\t\t\t\t
\n\t\t\n
\n\t\t\t
\n\t
\n\t
\n\t\t
\n\t\n\t\n\tDay 1 | 12:00<\/span>\n\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\t\t<\/span>\n\t\n\t\t\t\n\t\n\tEarly Phase Clinical Trials for Inhaled Drugs - Challenges and Opportunities<\/span>\n\n\t\t\t<\/a>\n\t\n\t\t\t<\/span>\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\n\t\t\t\n\t\n\tAernout van Haarst, PhD Director, Scientific Affairs at Celerion<\/span>\n\n\t\t\t<\/a>\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n<\/div>\n<\/div>\n\t\t\t
\n\t
\n\t
\n\t\t
\n\t\n\t\n\tDay 2 | 12:00<\/span>\n\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\t\t<\/span>\n\t\n\t\t\t\n\t\n\tOptimising surrogate outcome measures for respiratory trials<\/span>\n\n\t\t\t<\/a>\n\t\n\t\t\t<\/span>\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\n\t\t\t\n\t\n\tPeter Robbins Professor of Physiology at the University of Oxford<\/span>\n\n\t\t\t<\/a>\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n<\/div>\n<\/div>\n\t<\/div>\n\t\t<\/div>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t\t\t\t\t
\n\t\t\n
\n\t\t\t
\n\t
<\/div>\n<\/div>\n\t\t\t
\n\t
\n\t
\n\t\t

\n\t\t\t<\/span>\n\t\n\t\n\tPart IV: New analytical insights into dry powder formulations for inhalation<\/span>\n\n\t\n\t\t\t<\/span>\n\t<\/h4>\n\t<\/div>\n<\/div>\n<\/div>\n<\/div>\n\t<\/div>\n\n
\n\t\t\t
\n\t
\n\t
\n\t\t
\n\t\n\t\n\tDay 1 | 13:00<\/span>\n\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\t\t<\/span>\n\t\n\t\t\t\n\t\n\tAccurate dosimetry predictions for evolving liquid aerosol delivery<\/span>\n\n\t\t\t<\/a>\n\t\n\t\t\t<\/span>\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\n\t\t\t\n\t\n\tArkadiusz Kuczaj, PhD, Manager Aerosol Research and Dosimetry at Philip Morris International Research and Development<\/span>\n\n\t\t\t<\/a>\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n<\/div>\n<\/div>\n\t\t\t
\n\t
\n\t
\n\t\t
\n\t\n\t\n\tDay 2 | 13:00<\/span>\n\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\t\t<\/span>\n\t\n\t\t\t\n\t\n\tDigital Pharmaceuticals: A case study<\/span>\n\n\t\t\t<\/a>\n\t\n\t\t\t<\/span>\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\n\t\t\t\n\t\n\tMark Milton-Edwards, Head of Product & Health Solutions - Digital Health at Teva Pharmaceuticals<\/span>\n\n\t\t\t<\/a>\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n<\/div>\n<\/div>\n\t<\/div>\n\t\t<\/div>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t\t\t\t\t
\n\t\t\n
\n\t\t\t
\n\t
\n\t
\n\t\t

\n\t\t\t<\/span>\n\t\n\t\n\tPart II: Inhalation Formulation Solutions & Technology<\/span>\n\n\t\n\t\t\t<\/span>\n\t<\/h4>\n\t<\/div>\n<\/div>\n<\/div>\n<\/div>\n\t\t\t
\n\t
<\/div>\n<\/div>\n\t<\/div>\n\n
\n\t\t\t
\n\t
\n\t
\n\t\t
\n\t\n\t\n\tDay 1 | 14:00<\/span>\n\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\t\t<\/span>\n\t\n\t\t\t\n\t\n\tHigh Dosage DPI \u2013 formulation and process development considerations<\/span>\n\n\t\t\t<\/a>\n\t\n\t\t\t<\/span>\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\n\t\t\t\n\t\n\tBeatriz Noriega Fernandes, Scientist, Formulation Group - Drug Product Development at Hovione<\/span>\n\n\t\t\t<\/a>\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n<\/div>\n<\/div>\n\t\t\t
\n\t
\n\t
\n\t\t
\n\t\n\t\n\tDay 2 | 14:00<\/span>\n\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\t\t<\/span>\n\t\n\t\t\t\n\t\n\tARCUS\u00ae: Engineered Spray Dried Particles for Inhalation Delivery<\/span>\n\n\t\t\t<\/a>\n\t\n\t\t\t<\/span>\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\n\t\t\t\n\t\n\tMichael Tauber, Senior Director of Pharmaceutical Development and Technical Operations at Acorda Therapeutics<\/span>\n\n\t\t\t<\/a>\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n<\/div>\n<\/div>\n\t<\/div>\n\t\t<\/div>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t\t\t\t\t
\n\t\t\n
\n\t\t\t
\n\t
\n\t
\n\t\t
\n\t\n\t\n\tDay 1 | 15:00<\/span>\n\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\t\t<\/span>\n\t\n\t\t\t\n\t\n\tIncreasing the drug load in capsule based DPI drug delivery systems<\/span>\n\n\t\t\t<\/a>\n\t\n\t\t\t<\/span>\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\n\t\t\t\n\t\n\tProf. Dr. Sven Stegemann, Professor of patient centric drug design and manufacturing at the Graz University of Technology, Austria<\/span>\n\n\t\t\t<\/a>\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n<\/div>\n<\/div>\n\t\t\t
\n\t
\n\t
\n\t\t
\n\t\n\t\n\tDay 2 | 15:00<\/span>\n\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\t\t<\/span>\n\t\n\t\t\t\n\t\n\tMusings on High Dose Powder Delivery<\/span>\n\n\t\t\t<\/a>\n\t\n\t\t\t<\/span>\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\n\t\t\t\n\t\n\tJeffry Weers, Ph.D. Jeffry Weers, Chief Technical Officer at cystetic Medicines, Inc.<\/span>\n\n\t\t\t<\/a>\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n<\/div>\n<\/div>\n\t<\/div>\n\t\t<\/div>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t\t\t\t\t
\n\t\t\n
\n\t\t\t
\n\t
<\/div>\n<\/div>\n\t\t\t
\n\t
\n\t
\n\t\t

\n\t\t\t<\/span>\n\t\n\t\n\tPart V: New Approaches to Inhalation Product Development and Production<\/span>\n\n\t\n\t\t\t<\/span>\n\t<\/h4>\n\t<\/div>\n<\/div>\n<\/div>\n<\/div>\n\t<\/div>\n\n
\n\t\t\t
\n\t
\n\t
\n\t\t
\n\t\n\t\n\tDay 1 | 16:00<\/span>\n\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\t\t<\/span>\n\t\n\t\t\t\n\t\n\tFormulation Development Challenges and Pitfalls When Developing Dry Powder Inhalers<\/span>\n\n\t\t\t<\/a>\n\t\n\t\t\t<\/span>\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\n\t\t\t\n\t\n\tMartin Wing-King, Director of Project Management at Quotient Sciences<\/span>\n\n\t\t\t<\/a>\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n<\/div>\n<\/div>\n\t\t\t
\n\t
\n\t
\n\t\t
\n\t\n\t\n\tDay 2 | 16:00<\/span>\n\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\t\t<\/span>\n\t\n\t\t\t\n\t\n\tInhalation and Nasal routes as stairways to drug Innovation<\/span>\n\n\t\t\t<\/a>\n\t\n\t\t\t<\/span>\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\n\t\t\t\n\t\n\tHugo Almeida, International Business Development Consultant at AdAlvo (an Alvogen subsidiary)<\/span>\n\n\t\t\t<\/a>\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n<\/div>\n<\/div>\n\t<\/div>\n\t\t<\/div>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t\t\t\t\t
\n\t\t\n
\n\t\t\t
\n\t
\n\t
\n\t\t
\n\t\n\t\n\tDay 1 | 17:00<\/span>\n\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\t\t<\/span>\n\t\n\t\t\t\n\t\n\tThe development and supply of respiratory medicines<\/span>\n\n\t\t\t<\/a>\n\t\n\t\t\t<\/span>\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\n\t\t\t\n\t\n\tDavid Wyatt, Chief Operating Officer at Aston Particle Technologies<\/span>\n\n\t\t\t<\/a>\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n<\/div>\n<\/div>\n\t\t\t
\n\t
\n\t
\n\t\t
\n\t\n\t\n\tDay 2 | 17:00<\/span>\n\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\t\t<\/span>\n\t\n\t\t\t\n\t\n\tA lung-on-chip approach towards predictive in vitro inhalation<\/span>\n\n\t\t\t<\/a>\n\t\n\t\t\t<\/span>\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\n\t\t\t\n\t\n\tNuria Roldan, Project Leader at AlveoliX<\/span>\n\n\t\t\t<\/a>\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n<\/div>\n<\/div>\n\t<\/div>\n\t\t<\/div>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t\t\t\t\t
\n\t\t\n
\n\t\t\t
\n\t
\n\t
\n\t\t
\n\t\n\t\n\tDay 1 | 18:00<\/span>\n\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\t\t<\/span>\n\t\n\t\t\t\n\t\n\tGet it right first time: Inhaler technology and manufacturing<\/span>\n\n\t\t\t<\/a>\n\t\n\t\t\t<\/span>\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\n\t\t\t\n\t\n\tMarco Laackmann, Director Inhalation Technology at Harro H\u00f6fliger<\/span>\n\n\t\t\t<\/a>\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n<\/div>\n<\/div>\n\t\t\t
\n\t
\n\t
\n\t\t
\n\t\n\t\n\tDay 2 | 18:00<\/span>\n\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\t\t<\/span>\n\t\n\t\t\t\n\t\n\tScience base and challenges of therapeutic equivalence of respiratory products.<\/span>\n\n\t\t\t<\/a>\n\t\n\t\t\t<\/span>\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\n\t\t\t\n\t\n\tJ\u00f6rg Schiewe, Head of Global CMC Experts at Boehringer Ingelheim<\/span>\n\n\t\t\t<\/a>\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n<\/div>\n<\/div>\n\t<\/div>\n\t\t<\/div>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t\t\t\t\t
\n\t\t\n
\n\t\t\t
\n\t
\n\t
\n\t\t
\n\t\n\t\n\tDay 1 | 19:00<\/span>\n\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\t\t<\/span>\n\t\n\t\t\t\n\t\n\tMDPI for 2 API<\/span>\n\n\t\t\t<\/a>\n\t\n\t\t\t<\/span>\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\n\t\t\t\n\t\n\tMarkus Mezger, CEO at Mematec solutions<\/span>\n\n\t\t\t<\/a>\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n<\/div>\n<\/div>\n\t\t\t
\n\t
\n\t
\n\t\t
\n\t\n\t\n\tDay 2 | 19:00<\/span>\n\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\t\t<\/span>\n\t\n\t\t\t\n\t\n\tThe biological barriers to consider for the development of inhaled biotherapeutics<\/span>\n\n\t\t\t<\/a>\n\t\n\t\t\t<\/span>\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\n\t\t\t\n\t\n\tThomas Secher, Research scientist (CRCN) at INSERM<\/span>\n\n\t\t\t<\/a>\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n<\/div>\n<\/div>\n\t<\/div>\n\t\t<\/div>\n\t<\/div>\n<\/div>\n<\/div>\t\t\t\n\t\t\t\t
\n\t
\n\t\t\t\t\t\t
\n\t\t\n
\n\t\t\t
\n\t
\n\t
\n\t\t

\n\t\t\t<\/span>\n\t\n\t\n\tDay 1<\/span>\n\n\t\n\t\t\t<\/span>\n\t<\/h3>\n\t<\/div>\n<\/div>\n<\/div>\n<\/div>\n\t\t\t
\n\t
\n\t
\n\t\t

\n\t\t\t<\/span>\n\t\n\t\n\tDay 2<\/span>\n\n\t\n\t\t\t<\/span>\n\t<\/h3>\n\t<\/div>\n<\/div>\n<\/div>\n<\/div>\n\t<\/div>\n\n
\n\t\t\t
\n\t
\n\t
\n\t\t
\n\t\n\t\n\tDay 1 | 10:00<\/span>\n\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\t\t<\/span>\n\t\n\t\t\t\n\t\n\tPSMF in a global environment: compliance with local requirements<\/span>\n\n\t\t\t<\/a>\n\t\n\t\t\t<\/span>\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\n\t\t\t\n\t\n\tMargherita D'Antuono, Corporate Pharmacovigilance Director - EU QPPV at Italfarmaco Group<\/span>\n\n\t\t\t<\/a>\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n<\/div>\n<\/div>\n\t\t\t
\n\t
\n\t
\n\t\t
\n\t\n\t\n\tDay 2 | 10:00<\/span>\n\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\t\t<\/span>\n\t\n\t\t\t\n\t\n\tCommunicating safety safely: what can we learn from Covid-19?<\/span>\n\n\t\t\t<\/a>\n\t\n\t\t\t<\/span>\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\n\t\t\t\n\t\n\tUwe Gudat, Head of Medical Affairs & CSPV at Fresenius Kabi at Fresenius Kabi SwissBioSim GmbH<\/span>\n\n\t\t\t<\/a>\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n<\/div>\n<\/div>\n\t<\/div>\n\t\t<\/div>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t\t\t\t\t
\n\t\t\n
\n\t\t\t
\n\t
\n\t
\n\t\t
\n\t\n\t\n\tDay 1 | 11:00<\/span>\n\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\t\t<\/span>\n\t\n\t\t\t\n\t\n\tEudraVigilance, XEVMPD, EVDAS, SPOR, EMA unique account news<\/span>\n\n\t\t\t<\/a>\n\t\n\t\t\t<\/span>\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\n\t\t\t\n\t\n\tCalin Lungu, CEO at DDCS S.A.<\/span>\n\n\t\t\t<\/a>\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n<\/div>\n<\/div>\n\t\t\t
\n\t
\n\t
\n\t\t
\n\t\n\t\n\tDay 2 | 11:00<\/span>\n\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\t\t<\/span>\n\t\n\t\t\t\n\t\n\tNew Trends in Signal Detection and Management<\/span>\n\n\t\t\t<\/a>\n\t\n\t\t\t<\/span>\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\n\t\t\t\n\t\n\tRobert Weber, Product Management Director at Oracle<\/span>\n\n\t\t\t<\/a>\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n<\/div>\n<\/div>\n\t<\/div>\n\t\t<\/div>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t\t\t\t\t
\n\t\t\n
\n\t\t\t
\n\t
\n\t
\n\t\t
\n\t\n\t\n\tDay 1 | 12:00<\/span>\n\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\t\t<\/span>\n\t\n\t\t\t\n\t\n\tHow to define PV strategy and build an effective Regulatory Intelligence function<\/span>\n\n\t\t\t<\/a>\n\t\n\t\t\t<\/span>\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\n\t\t\t\n\t\n\tJulia Appelskog, Pharmacovigilance Director, EU QPPV, Head of QPPVs & Safety Consulting Services at TFS<\/span>\n\n\t\t\t<\/a>\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n<\/div>\n<\/div>\n\t\t\t
\n\t
\n\t
\n\t\t
\n\t\n\t\n\tDay 2 | 12:00<\/span>\n\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\t\t<\/span>\n\t\n\t\t\t\n\t\n\tThe Evolution of the Safety Scientist<\/span>\n\n\t\t\t<\/a>\n\t\n\t\t\t<\/span>\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\n\t\t\t\n\t\n\tDennis Vargo, Vice President and Head of Drug Safety and Pharmacovigilance at Akebia<\/span>\n\n\t\t\t<\/a>\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n<\/div>\n<\/div>\n\t<\/div>\n\t\t<\/div>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t\t\t\t\t
\n\t\t\n
\n\t\t\t
\n\t
\n\t
\n\t\t
\n\t\n\t\n\tDay 1 | 14:00<\/span>\n\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\t\t<\/span>\n\t\n\t\t\t\n\t\n\tAdoption of Artificial Intelligence in Pharmacovigilance: a framework for the development of cognitive services and the role of the Drug Safety Professional<\/span>\n\n\t\t\t<\/a>\n\t\n\t\t\t<\/span>\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\n\t\t\t\n\t\n\tSalvatore Cicirello, Head of Safety Science & PASS, Global Drug Safety & Risk Management at Bristol Myers Squibb<\/span>\n\n\t\t\t<\/a>\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n<\/div>\n<\/div>\n\t\t\t
\n\t
\n\t
\n\t\t
\n\t\n\t\n\tDay 2 | 14:00<\/span>\n\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\t\t<\/span>\n\t\n\t\t\t\n\t\n\tPV challenges during pandemic: <\/span>\n\n\t\t\t<\/a>\n\t\n\t\t\t<\/span>\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\n\t\t\t\n\t\n\tMircea Ciuca, Global Therapeutic Area Head - Global Clinical Safety and Pharmacovigilance at CSL Behring<\/span>\n\n\t\t\t<\/a>\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n<\/div>\n<\/div>\n\t<\/div>\n\t\t<\/div>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t\t\t\t\t
\n\t\t\n
\n\t\t\t
\n\t
\n\t
\n\t\t
\n\t\n\t\n\tDay 1 | 15:00<\/span>\n\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\t\t<\/span>\n\t\n\t\t\t\n\t\n\tSynergies between Regulatory Affairs and Pharmacovigilance<\/span>\n\n\t\t\t<\/a>\n\t\n\t\t\t<\/span>\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\n\t\t\t\n\t\n\tBudhesh Dhamija, Senior Manager, Regulatory Intelligence and Policy \u2013 Europe at CSL Behring<\/span>\n\n\t\t\t<\/a>\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n<\/div>\n<\/div>\n\t\t\t
\n\t
\n\t
\n\t\t
\n\t\n\t\n\tDay 2 | 15:00<\/span>\n\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\t\t<\/span>\n\t\n\t\t\t\n\t\n\tCardiovascular safety issues during phase III-IV for non-cardiovascular trials.<\/span>\n\n\t\t\t<\/a>\n\t\n\t\t\t<\/span>\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\n\t\t\t\n\t\n\tAnupam Agarwal, Vice President, Global Head of Drug Safety and Pharmacovigilance at Zogenix, Inc.<\/span>\n\n\t\t\t<\/a>\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n<\/div>\n<\/div>\n\t<\/div>\n\t\t<\/div>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t\t\t\t\t
\n\t\t\n
\n\t\t\t
\n\t
\n\t
\n\t\t
\n\t\n\t\n\tDay 1 | 16:00<\/span>\n\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\t\t<\/span>\n\t\n\t\t\t\n\t\n\tHow Pharmacovigilance could support business<\/span>\n\n\t\t\t<\/a>\n\t\n\t\t\t<\/span>\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\n\t\t\t\n\t\n\tAndrea Oliva, Head of Pharmacovigilance at Mylan<\/span>\n\n\t\t\t<\/a>\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n<\/div>\n<\/div>\n\t\t\t
\n\t
\n\t
\n\t\t
\n\t\n\t\n\tDay 2 | 16:00<\/span>\n\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\t\t<\/span>\n\t\n\t\t\t\n\t\n\tStructured and Quantitative Benefit-Risk evaluation for medicinal products: how can it make a difference?<\/span>\n\n\t\t\t<\/a>\n\t\n\t\t\t<\/span>\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\n\t\t\t\n\t\n\tMarie-Laure K\u00fcrzinger, Benefit-Risk Expert - Global Epidemiology & Benefit-Risk Evaluation - Global Pharmacovigilance at Sanofi<\/span>\n\n\t\t\t<\/a>\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n<\/div>\n<\/div>\n\t<\/div>\n\t\t<\/div>\n\t<\/div>\n<\/div>\n<\/div>\t\t\t\n\t\t\t\t
\n\t
\n\t\t\t\t\t\t
\n\t\t\n
\n\t\t\t
\n\t
\n\t
\n\t\t

\n\t\t\t<\/span>\n\t\n\t\n\tDay 1<\/span>\n\n\t\n\t\t\t<\/span>\n\t<\/h3>\n\t<\/div>\n<\/div>\n<\/div>\n<\/div>\n\t\t\t
\n\t
\n\t
\n\t\t

\n\t\t\t<\/span>\n\t\n\t\n\tDay 2<\/span>\n\n\t\n\t\t\t<\/span>\n\t<\/h3>\n\t<\/div>\n<\/div>\n<\/div>\n<\/div>\n\t<\/div>\n\n
\n\t\t\t
\n\t
\n\t
\n\t\t
\n\t\n\t\n\tDay 1 | 09:00<\/span>\n\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\t\t<\/span>\n\t\n\t\t\t\n\t\n\tUser-driven product development: Focus on self-injection devices<\/span>\n\n\t\t\t<\/a>\n\t\n\t\t\t<\/span>\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\n\t\t\t\n\t\n\tJakob Lange, Account Director at Ypsomed AG<\/span>\n\n\t\t\t<\/a>\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n<\/div>\n<\/div>\n\t\t\t
\n\t
\n\t
\n\t\t
\n\t\n\t\n\tDay 2 | 09:00<\/span>\n\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\t\t<\/span>\n\t\n\t\t\t\n\t\n\tInnovation through Miniaturization and Micro Injection Molding<\/span>\n\n\t\t\t<\/a>\n\t\n\t\t\t<\/span>\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\n\t\t\t\n\t\n\tAaron Johnson, Vice President of Marketing and Customer Strategy at Accumold<\/span>\n\n\t\t\t<\/a>\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n<\/div>\n<\/div>\n\t<\/div>\n\t\t<\/div>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t\t\t\t\t
\n\t\t\n
\n\t\t\t
\n\t
\n\t
\n\t\t
\n\t\n\t\n\tDay 1 | 10:00<\/span>\n\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\t\t<\/span>\n\t\n\t\n\tNext generation design and materials for PFS<\/span>\n\n\t\n\t\t\t<\/span>\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\n\t\t\t\n\t\n\tAmber Witteman, Inventor, Founder, Managing Director at EPIWatch<\/span>\n\n\t\t\t<\/a>\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n<\/div>\n<\/div>\n\t\t\t
\n\t
\n\t
\n\t\t
\n\t\n\t\n\tDay 2 | 10:00<\/span>\n\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\t\t<\/span>\n\t\n\t\t\t\n\t\n\tModular Feeding Systems for Parenterals, such as Pre-filled Syringes and Injection Devices<\/span>\n\n\t\t\t<\/a>\n\t\n\t\t\t<\/span>\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\n\t\t\t\n\t\n\tAshley Reynolds, Pharma Technology Sales and Marketing at K\u00f6rber Group company<\/span>\n\n\t\t\t<\/a>\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n<\/div>\n<\/div>\n\t<\/div>\n\t\t<\/div>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t\t\t\t\t
\n\t\t\n
\n\t\t\t
\n\t
\n\t
\n\t\t
\n\t\n\t\n\tDay 1 | 11:00<\/span>\n\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\t\t<\/span>\n\t\n\t\t\t\n\t\n\tNext generation design and materials for PFS<\/span>\n\n\t\t\t<\/a>\n\t\n\t\t\t<\/span>\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\n\t\t\t\n\t\n\tAmber Witteman, Inventor, Founder, Managing Director at EPIWatch<\/span>\n\n\t\t\t<\/a>\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n<\/div>\n<\/div>\n\t\t\t
\n\t
\n\t
\n\t\t
\n\t\n\t\n\tDay 2 | 11:00<\/span>\n\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\t\t<\/span>\n\t\n\t\t\t\n\t\n\tDeveloping suspensions as long acting injectables<\/span>\n\n\t\t\t<\/a>\n\t\n\t\t\t<\/span>\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\n\t\t\t\n\t\n\tRen\u00e9 Holm, Head and Scientific Director, Liquids & Parenterals at The Janssen Pharmaceutical Companies of Johnson & Johnson<\/span>\n\n\t\t\t<\/a>\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n<\/div>\n<\/div>\n\t<\/div>\n\t\t<\/div>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t\t\t\t\t
\n\t\t\n
\n\t\t\t
\n\t
\n\t
\n\t\t
\n\t\n\t\n\tDay 1 | 12:00<\/span>\n\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\t\t<\/span>\n\t\n\t\t\t\n\t\n\tExtractable metals: potential sources in your Prefilled Syringes, risk management and change control<\/span>\n\n\t\t\t<\/a>\n\t\n\t\t\t<\/span>\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\n\t\t\t\n\t\n\tBeate Treffler, Market Development Manager Healthcare EMEA at Avient Corporation<\/span>\n\n\t\t\t<\/a>\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n<\/div>\n<\/div>\n\t\t\t
\n\t
\n\t
\n\t\t
\n\t\n\t\n\tDay 2 | 12:00<\/span>\n\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\t\t<\/span>\n\t\n\t\t\t\n\t\n\tLong-Acting Injectable Formulation Technologies: Challenges and Opportunities for the Delivery of Fragile Molecules<\/span>\n\n\t\t\t<\/a>\n\t\n\t\t\t<\/span>\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\n\t\t\t\n\t\n\tJo\u00ebl Richard, Chief Development Officer at MedinCell<\/span>\n\n\t\t\t<\/a>\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n<\/div>\n<\/div>\n\t<\/div>\n\t\t<\/div>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t\t\t\t\t
\n\t\t\n
\n\t\t\t
\n\t
\n\t
\n\t\t
\n\t\n\t\n\tDay 1 | 13:00<\/span>\n\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\t\t<\/span>\n\t\n\t\t\t\n\t\n\tImpact of the EU MDR 2017\/745<\/span>\n\n\t\t\t<\/a>\n\t\n\t\t\t<\/span>\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\n\t\t\t\n\t\n\tBassil Akra, CEO at AKRA TEAM GmbH<\/span>\n\n\t\t\t<\/a>\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n<\/div>\n<\/div>\n\t\t\t
\n\t
\n\t
\n\t\t
\n\t\n\t\n\tDay 2 | 13:00<\/span>\n\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\t\t<\/span>\n\t\n\t\t\t\n\t\n\tAseptic Production and IPC<\/span>\n\n\t\t\t<\/a>\n\t\n\t\t\t<\/span>\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\n\t\t\t\n\t\n\tAndreas Kerschbaumer, Senior Technical Manager at Sandoz GmbH<\/span>\n\n\t\t\t<\/a>\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n<\/div>\n<\/div>\n\t<\/div>\n\t\t<\/div>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t\t\t\t\t
\n\t\t\n
\n\t\t\t
\n\t
\n\t
\n\t\t
\n\t\n\t\n\tDay 1 | 14:00<\/span>\n\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\t\t<\/span>\n\t\n\t\t\t\n\t\n\tA forward looking approach towards design & development of patient-centric autoinjectors<\/span>\n\n\t\t\t<\/a>\n\t\n\t\t\t<\/span>\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\n\t\t\t\n\t\n\tAsmita Khanolkar, Senior Director, Cambridge Pharma at SMC Ltd<\/span>\n\n\t\t\t<\/a>\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n<\/div>\n<\/div>\n\t\t\t
\n\t
\n\t
\n\t\t
\n\t\n\t\n\tDay 2 | 14:00<\/span>\n\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\t\t<\/span>\n\t\n\t\t\t\n\t\n\tBeyond glass \u2013 benefits for biological drugs of a new hybrid material for primary packaging container<\/span>\n\n\t\t\t<\/a>\n\t\n\t\t\t<\/span>\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\n\t\t\t\n\t\n\tHolger Krenz Vice President Applications Development Europe at SiO2 Material Science<\/span>\n\n\t\t\t<\/a>\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n<\/div>\n<\/div>\n\t<\/div>\n\t\t<\/div>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t\t\t\t\t
\n\t\t\n
\n\t\t\t
\n\t
\n\t
\n\t\t
\n\t\n\t\n\tDay 1 | 15:00<\/span>\n\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\t\t<\/span>\n\t\n\t\t\t\n\t\n\tNonclinical safety evaluation of extractables and leachables when developing a pre-filled syringe drug device combination product<\/span>\n\n\t\t\t<\/a>\n\t\n\t\t\t<\/span>\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\n\t\t\t\n\t\n\tClemens G\u00fcnther, Director Senior Expert Nonclinical Safety at Bayer AG<\/span>\n\n\t\t\t<\/a>\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n<\/div>\n<\/div>\n\t\t\t
\n\t
\n\t
\n\t\t
\n\t\n\t\n\tDay 2 | 15:00<\/span>\n\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\t\t<\/span>\n\t\n\t\t\t\n\t\n\tAn industrial perspective for fill & finish of nested syringes<\/span>\n\n\t\t\t<\/a>\n\t\n\t\t\t<\/span>\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\n\t\t\t\n\t\n\tFranz Kainz, PhD Vice President, Global Contract Manufacturing at Fresenius Kabi Deutschland GmbH<\/span>\n\n\t\t\t<\/a>\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n<\/div>\n<\/div>\n\t<\/div>\n\t\t<\/div>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t\t\t\t\t
\n\t\t\n
\n\t\t\t
\n\t
\n\t
\n\t\t
\n\t\n\t\n\tDay 1 | 16:00<\/span>\n\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\t\t<\/span>\n\t\n\t\t\t\n\t\n\tExtractables & Leachables Qualification in Pre-Filled Syringes<\/span>\n\n\t\t\t<\/a>\n\t\n\t\t\t<\/span>\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\n\t\t\t\n\t\n\tRaphael Nudelman, Senior Director Impurity Expert, R&D Operations at Teva Pharmaceuticals<\/span>\n\n\t\t\t<\/a>\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n<\/div>\n<\/div>\n\t\t\t
\n\t
\n\t
\n\t\t
\n\t\n\t\n\t.<\/span>\n\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n<\/div>\n<\/div>\n\t<\/div>\n\t\t<\/div>\n\t<\/div>\n<\/div>\n<\/div>\t\t\t\n\t\t\t\t
\n\t
\n\t\t\t\t\t\t
\n\t\t\n
\n\t\t\t
\n\t
\n\t
\n\t\t

\n\t\t\t<\/span>\n\t\n\t\n\tDay 1<\/span>\n\n\t\n\t\t\t<\/span>\n\t<\/h3>\n\t<\/div>\n<\/div>\n<\/div>\n<\/div>\n\t\t\t
\n\t
\n\t
\n\t\t

\n\t\t\t<\/span>\n\t\n\t\n\tDay 2<\/span>\n\n\t\n\t\t\t<\/span>\n\t<\/h3>\n\t<\/div>\n<\/div>\n<\/div>\n<\/div>\n\t<\/div>\n\n
\n\t\t\t
\n\t
\n\t
\n\t\t
\n\t\n\t\n\tDay 1 | 09:00<\/span>\n\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\t\t<\/span>\n\t\n\t\t\t\n\t\n\tCan a diet tackle stress?<\/span>\n\n\t\t\t<\/a>\n\t\n\t\t\t<\/span>\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\n\t\t\t\n\t\n\tNadejda Lupolova, Health Coach<\/span>\n\n\t\t\t<\/a>\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n<\/div>\n<\/div>\n\t\t\t
\n\t
\n\t
\n\t\t
\n\t\n\t\n\tDay 2 | 09:00<\/span>\n\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\t\t<\/span>\n\t\n\t\t\t\n\t\n\tHarnessing the Potential of Microbiota-related Therapies for Brain Health<\/span>\n\n\t\t\t<\/a>\n\t\n\t\t\t<\/span>\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\n\t\t\t\n\t\n\tJane A. Foster, Associate Professor at McMaster University<\/span>\n\n\t\t\t<\/a>\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n<\/div>\n<\/div>\n\t<\/div>\n\t\t<\/div>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t\t\t\t\t
\n\t\t\n
\n\t\t\t
\n\t
\n\t
\n\t\t
\n\t\n\t\n\tDay 1 | 10:00<\/span>\n\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\t\t<\/span>\n\t\n\t\t\t\n\t\n\tMechanisms and current evidence of prebiotics in gut-brain-axis<\/span>\n\n\t\t\t<\/a>\n\t\n\t\t\t<\/span>\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\n\t\t\t\n\t\n\tDr. Yoghatama Zanzer, Manager Nutrition Science at BENEO, Germany<\/span>\n\n\t\t\t<\/a>\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n<\/div>\n<\/div>\n\t\t\t
\n\t
\n\t
\n\t\t
\n\t\n\t\n\tDay 2 | 10:00<\/span>\n\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\t\t<\/span>\n\t\n\t\t\t\n\t\n\tPioneering precision probiotics: from molecular mimetism to product commercialization<\/span>\n\n\t\t\t<\/a>\n\t\n\t\t\t<\/span>\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\n\t\t\t\n\t\n\tNina Vinot, International Sales Director at TargEDys<\/span>\n\n\t\t\t<\/a>\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n<\/div>\n<\/div>\n\t<\/div>\n\t\t<\/div>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t\t\t\t\t
\n\t\t\n
\n\t\t\t
\n\t
\n\t
\n\t\t
\n\t\n\t\n\tDay 1 | 11:00<\/span>\n\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\t\t<\/span>\n\t\n\t\t\t\n\t\n\tLeveraging the microbiome in Alzheimer's disease progression and neuroinflammation<\/span>\n\n\t\t\t<\/a>\n\t\n\t\t\t<\/span>\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\n\t\t\t\n\t\n\tAlessio Mylonas, Research Scientist at AC Immune<\/span>\n\n\t\t\t<\/a>\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n<\/div>\n<\/div>\n\t\t\t
\n\t
\n\t
\n\t\t
\n\t\n\t\n\tDay 2 | 11:00<\/span>\n\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\t\t<\/span>\n\t\n\t\t\t\n\t\n\tThe gut-brain and brain-gut axes in human disease<\/span>\n\n\t\t\t<\/a>\n\t\n\t\t\t<\/span>\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\n\t\t\t\n\t\n\tWouter de Jonge, Professor of Neurogastroenterology at AMC, CoFounder of Gut Research<\/span>\n\n\t\t\t<\/a>\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n<\/div>\n<\/div>\n\t<\/div>\n\t\t<\/div>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t\t\t\t\t
\n\t\t\n
\n\t\t\t
\n\t
\n\t
\n\t\t
\n\t\n\t\n\tDay 1 | 12:00<\/span>\n\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\t\t<\/span>\n\t\n\t\t\t\n\t\n\tThe gut microbiome as a therapeutic venue for inflammatory diseases of the central nervous system (CNS)<\/span>\n\n\t\t\t<\/a>\n\t\n\t\t\t<\/span>\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\n\t\t\t\n\t\n\tJavier Ochoa-Repa\u0301raz, Associate Professor at Eastern Washington University<\/span>\n\n\t\t\t<\/a>\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n<\/div>\n<\/div>\n\t\t\t
\n\t
\n\t
\n\t\t
\n\t\n\t\n\tDay 2 | 12:00<\/span>\n\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\t\t<\/span>\n\t\n\t\t\t\n\t\n\tMolecular Mimicry of microbial and dietary immune triggers as the key to disease complexity in Parkinson's<\/span>\n\n\t\t\t<\/a>\n\t\n\t\t\t<\/span>\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\n\t\t\t\n\t\n\tMartha Carlin, Chief Executive Officer at The BioCollective<\/span>\n\n\t\t\t<\/a>\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n<\/div>\n<\/div>\n\t<\/div>\n\t\t<\/div>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t\t\t\t\t
\n\t\t\n
\n\t\t\t
\n\t
\n\t
\n\t\t
\n\t\n\t\n\tDay 1 | 13:00<\/span>\n\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\t\t<\/span>\n\t\n\t\t\t\n\t\n\tImmuneBiotics for management of neurological conditions \u2013 new clinical evidence<\/span>\n\n\t\t\t<\/a>\n\t\n\t\t\t<\/span>\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\n\t\t\t\n\t\n\tShahram Lavasani, Founder and CEO at ImmuneBiotech AB<\/span>\n\n\t\t\t<\/a>\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n<\/div>\n<\/div>\n\t\t\t
\n\t
\n\t
\n\t\t
\n\t\n\t\n\tDay 2 | 13:00<\/span>\n\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\t\t<\/span>\n\t\n\t\t\t\n\t\n\tMicrobiome Mediated Appetite Regulation - First Experiences with EnteroSatys<\/span>\n\n\t\t\t<\/a>\n\t\n\t\t\t<\/span>\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\n\t\t\t\n\t\n\tDr. Sergue\u00ef O. Fetissov, Professor of physiology at Rouen University and co-founder of TargEDys.<\/span>\n\n\t\t\t<\/a>\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n<\/div>\n<\/div>\n\t<\/div>\n\t\t<\/div>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t\t\t\t\t
\n\t\t\n
\n\t\t\t
\n\t
\n\t
\n\t\t
\n\t\n\t\n\tDay 1 | 14:00<\/span>\n\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\t\t<\/span>\n\t\n\t\t\t\n\t\n\tNovel Microbiome Approach For Management of Alzheimer Diseases<\/span>\n\n\t\t\t<\/a>\n\t\n\t\t\t<\/span>\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\n\t\t\t\n\t\n\tSatya Prakash, Professor of Biomedical Engineering, Artificial Cells and Organs, Physiology, Experimental Medicine and Surgury in the Faculty of Medicine at McGill University<\/span>\n\n\t\t\t<\/a>\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n<\/div>\n<\/div>\n\t\t\t
\n\t
\n\t
\n\t\t
\n\t\n\t\n\tDay 2 | 14:00<\/span>\n\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\t\t<\/span>\n\t\n\t\t\t\n\t\n\tDiet & the Gut-Brain Axis: from concept to product<\/span>\n\n\t\t\t<\/a>\n\t\n\t\t\t<\/span>\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\n\t\t\t\n\t\n\tMarcus B\u00f6hme, R&D Specialist at Nestl\u00e9 Research<\/span>\n\n\t\t\t<\/a>\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n<\/div>\n<\/div>\n\t<\/div>\n\t\t<\/div>\n\t<\/div>\n<\/div>\n<\/div>\t\t\t\n\t\t\t\t
\n\t
\n\t\t\t\t\t\t
\n\t\t\n
\n\t\t\t
\n\t
\n\t
\n\t\t

\n\t\t\t<\/span>\n\t\n\t\n\tDay 1<\/span>\n\n\t\n\t\t\t<\/span>\n\t<\/h3>\n\t<\/div>\n<\/div>\n<\/div>\n<\/div>\n\t\t\t
\n\t
\n\t
\n\t\t

\n\t\t\t<\/span>\n\t\n\t\n\tDay 2<\/span>\n\n\t\n\t\t\t<\/span>\n\t<\/h3>\n\t<\/div>\n<\/div>\n<\/div>\n<\/div>\n\t<\/div>\n\n
\n\t\t\t
\n\t
\n\t
\n\t\t
\n\t\n\t\n\tDay 1 | 09:00<\/span>\n\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\t\t<\/span>\n\t\n\t\t\t\n\t\n\tDeveloping global standards for the microbiome field<\/span>\n\n\t\t\t<\/a>\n\t\n\t\t\t<\/span>\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\n\t\t\t\n\t\n\tChrysi Sergaki, Microbiome Scientist at National Institute for Biological Standards and Control (NIBSC\/MHRA)<\/span>\n\n\t\t\t<\/a>\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n<\/div>\n<\/div>\n\t\t\t
\n\t
\n\t
\n\t\t
\n\t\n\t\n\tDay 2 | 09:00<\/span>\n\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\t\t<\/span>\n\t\n\t\t\t\n\t\n\tConsidering the Microbiome Interorgans Axis (MIA) as a future option in Health & Diseases<\/span>\n\n\t\t\t<\/a>\n\t\n\t\t\t<\/span>\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\n\t\t\t\n\t\n\tLionel Breton, Cofounder and executive VP of IDEC therapeutics<\/span>\n\n\t\t\t<\/a>\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n<\/div>\n<\/div>\n\t<\/div>\n\t\t<\/div>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t\t\t\t\t
\n\t\t\n
\n\t\t\t
\n\t
\n\t
\n\t\t
\n\t\n\t\n\tDay 1 | 10:00<\/span>\n\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\t\t<\/span>\n\t\n\t\t\t\n\t\n\tQuality control of probiotics and internationalisation of the ESLP initiative<\/span>\n\n\t\t\t<\/a>\n\t\n\t\t\t<\/span>\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\n\t\t\t\n\t\n\tJean-Pol Warz\u00e9e, President at European Scientific League for Probiotics \u2013 ESLP<\/span>\n\n\t\t\t<\/a>\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n<\/div>\n<\/div>\n\t\t\t
\n\t
\n\t
\n\t\t
\n\t\n\t\n\tDay 2 | 10:00<\/span>\n\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\t\t<\/span>\n\t\n\t\t\t\n\t\n\tS-Biomedic approach of direct skin microbiome modulation<\/span>\n\n\t\t\t<\/a>\n\t\n\t\t\t<\/span>\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\n\t\t\t\n\t\n\tVeronika Oudova, Co-founder and Chief Executive Officer at S-Biomedic<\/span>\n\n\t\t\t<\/a>\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n<\/div>\n<\/div>\n\t<\/div>\n\t\t<\/div>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t\t\t\t\t
\n\t\t\n
\n\t\t\t
\n\t
\n\t
\n\t\t
\n\t\n\t\n\tDay 1 | 11:00<\/span>\n\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\t\t<\/span>\n\t\n\t\t\t\n\t\n\tUnravelling the microbiome of inflammatory bowel disease<\/span>\n\n\t\t\t<\/a>\n\t\n\t\t\t<\/span>\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\n\t\t\t\n\t\n\tMarcus Claesson, Chief Executive Officer at SeqBiome<\/span>\n\n\t\t\t<\/a>\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n<\/div>\n<\/div>\n\t\t\t
\n\t
\n\t
\n\t\t
\n\t\n\t\n\tDay 2 | 11:00<\/span>\n\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\t\t<\/span>\n\t\n\t\t\t\n\t\n\tThe human microbiome is not an island.<\/span>\n\n\t\t\t<\/a>\n\t\n\t\t\t<\/span>\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\n\t\t\t\n\t\n\tNewton Gomes Researcher University of Aveiro\/Co-founder at InnerCore Microbiome<\/span>\n\n\t\t\t<\/a>\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n<\/div>\n<\/div>\n\t<\/div>\n\t\t<\/div>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t\t\t\t\t
\n\t\t\n
\n\t\t\t
\n\t
\n\t
\n\t\t
\n\t\n\t\n\tDay 1 | 12:00<\/span>\n\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\t\t<\/span>\n\t\n\t\t\t\n\t\n\tMeasuring the microbiome: Path towards products that work in balance with the microbiome<\/span>\n\n\t\t\t<\/a>\n\t\n\t\t\t<\/span>\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\n\t\t\t\n\t\n\tDr. Eline Klaassens, Product Manager Human Health at BaseClear B.V.<\/span>\n\n\t\t\t<\/a>\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n<\/div>\n<\/div>\n\t\t\t
\n\t
\n\t
\n\t\t
\n\t\n\t\n\tDay 2 | 12:00<\/span>\n\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\t\t<\/span>\n\t\n\t\t\t\n\t\n\tTopical rosemary extract containing carnosic acid inhibits Staphylococcus aureus virulence in vitro and reduces the signs and symptoms of adult skin irritation and eczema in a randomized, double-blind, vehicle-controlled pilot study.<\/span>\n\n\t\t\t<\/a>\n\t\n\t\t\t<\/span>\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\n\t\t\t\n\t\n\tGreg Hillebrand, Senior Principal Research Scientist at Amway<\/span>\n\n\t\t\t<\/a>\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n<\/div>\n<\/div>\n\t<\/div>\n\t\t<\/div>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t\t\t\t\t
\n\t\t\n
\n\t\t\t
\n\t
\n\t
\n\t\t
\n\t\n\t\n\tDay 1 | 13:00<\/span>\n\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\t\t<\/span>\n\t\n\t\t\t\n\t\n\tThe underarm microbiome and the development of new probiotics<\/span>\n\n\t\t\t<\/a>\n\t\n\t\t\t<\/span>\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\n\t\t\t\n\t\n\tDr Chris Callewaert, Senior Post-doctoral Researcher at Ghent University, Belgium<\/span>\n\n\t\t\t<\/a>\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n<\/div>\n<\/div>\n\t\t\t
\n\t
\n\t
\n\t\t
\n\t\n\t\n\tDay 2 | 13:00<\/span>\n\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\t\t<\/span>\n\t\n\t\t\t\n\t\n\tScalp Microbiome, how to develop specific products, and for what results?<\/span>\n\n\t\t\t<\/a>\n\t\n\t\t\t<\/span>\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\n\t\t\t\n\t\n\tMarie Drago, Founder at Gallin\u00e9e<\/span>\n\n\t\t\t<\/a>\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n<\/div>\n<\/div>\n\t<\/div>\n\t\t<\/div>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t\t\t\t\t
\n\t\t\n
\n\t\t\t
\n\t
\n\t
\n\t\t
\n\t\n\t\n\tDay 1 | 14:00<\/span>\n\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\t\t<\/span>\n\t\n\t\t\t\n\t\n\tMicrobes and the Skin: Science, Regulation and the Marketplace<\/span>\n\n\t\t\t<\/a>\n\t\n\t\t\t<\/span>\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\n\t\t\t\n\t\n\tGeorge Paraskevakos, Executive Director at International Probiotics Association (IPA)<\/span>\n\n\t\t\t<\/a>\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n<\/div>\n<\/div>\n\t\t\t
\n\t
\n\t
\n\t\t
\n\t\n\t\n\tDay 2 | 14:00<\/span>\n\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\t\t<\/span>\n\t\n\t\t\t\n\t\n\tPlatform that allows to study the connections among diet, gut microbiome, immune system, human physiology, and health\/disease states<\/span>\n\n\t\t\t<\/a>\n\t\n\t\t\t<\/span>\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\n\t\t\t\n\t\n\tMomo Vuyisich, Founder and Chief Science Officer at Viome<\/span>\n\n\t\t\t<\/a>\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n<\/div>\n<\/div>\n\t<\/div>\n\t\t<\/div>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t\t\t\t\t
\n\t\t\n
\n\t\t\t
\n\t
\n\t
\n\t\t
\n\t\n\t\n\tDay 1 | 15:00<\/span>\n\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\t\t<\/span>\n\t\n\t\t\t\n\t\n\tFertibiome, a probiotic for couples with infertility problems.<\/span>\n\n\t\t\t<\/a>\n\t\n\t\t\t<\/span>\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\n\t\t\t\n\t\n\tSergio Esteban, Project Manager at Probisearch SLU<\/span>\n\n\t\t\t<\/a>\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n<\/div>\n<\/div>\n\t\t\t
\n\t
\n\t
\n\t\t
\n\t\n\t\n\tDay 2 | 15:00<\/span>\n\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\t\t<\/span>\n\t\n\t\t\t\n\t\n\tAmmonia Oxidizing Bacteria as a Treatment for Inflammatory Skin Disease<\/span>\n\n\t\t\t<\/a>\n\t\n\t\t\t<\/span>\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\n\t\t\t\n\t\n\tDaniel Brownell, Director, Research & Development at AOBiome Therapeutics<\/span>\n\n\t\t\t<\/a>\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n<\/div>\n<\/div>\n\t<\/div>\n\t\t<\/div>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t\t\t\t\t
\n\t\t\n
\n\t\t\t
\n\t
\n\t
\n\t\t
\n\t\n\t\n\tDay 1 | 16:00<\/span>\n\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\t\t<\/span>\n\t\n\t\t\t\n\t\n\tStudying the variability of intestinal microbiome in mice to better understand the Human microbiome<\/span>\n\n\t\t\t<\/a>\n\t\n\t\t\t<\/span>\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\n\t\t\t\n\t\n\tPavlovic Guillaume, Head of Unit at PHENOMIN-ICS<\/span>\n\n\t\t\t<\/a>\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n<\/div>\n<\/div>\n\t\t\t
\n\t
\n\t
\n\t\t
\n\t\n\t\n\t.<\/span>\n\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n<\/div>\n<\/div>\n\t<\/div>\n\t\t<\/div>\n\t<\/div>\n<\/div>\n<\/div>\t\t\t\n\t\t\t\t
\n\t
\n\t\t\t\t\t\t
\n\t\t\n
\n\t\t\t
\n\t
\n\t
\n\t\t

\n\t\t\t<\/span>\n\t\n\t\n\tDay 1<\/span>\n\n\t\n\t\t\t<\/span>\n\t<\/h3>\n\t<\/div>\n<\/div>\n<\/div>\n<\/div>\n\t\t\t
\n\t
\n\t
\n\t\t

\n\t\t\t<\/span>\n\t\n\t\n\tDay 2<\/span>\n\n\t\n\t\t\t<\/span>\n\t<\/h3>\n\t<\/div>\n<\/div>\n<\/div>\n<\/div>\n\t<\/div>\n\n
\n\t\t\t
\n\t
\n\t
\n\t\t
\n\t\n\t\n\tDay 1 | 09:00<\/span>\n\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\t\t<\/span>\n\t\n\t\t\t\n\t\n\tVaccines for the world - insights into design and execution of a BSL2 fill-finish facility<\/span>\n\n\t\t\t<\/a>\n\t\n\t\t\t<\/span>\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\n\t\t\t\n\t\n\tMatthias Angelmaier, Global Product Manager Isolator Technology at Syntegon Technology GmbH<\/span>\n\n\t\t\t<\/a>\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n<\/div>\n<\/div>\n\t\t\t
\n\t
\n\t
\n\t\t
\n\t\n\t\n\tDay 2 | 09:00<\/span>\n\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\t\t<\/span>\n\t\n\t\t\t\n\t\n\tContinuous Processing opening new possibilities<\/span>\n\n\t\t\t<\/a>\n\t\n\t\t\t<\/span>\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\n\t\t\t\n\t\n\tHarald Stahl, Senior Director Innovation and Strategy at GEA AG<\/span>\n\n\t\t\t<\/a>\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n<\/div>\n<\/div>\n\t<\/div>\n\t\t<\/div>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t\t\t\t\t
\n\t\t\n
\n\t\t\t
\n\t
\n\t
\n\t\t
\n\t\n\t\n\tDay 1 | 10:00<\/span>\n\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\t\t<\/span>\n\t\n\t\t\t\n\t\n\tClosed process for aseptic fill without possibility for sterile filtration<\/span>\n\n\t\t\t<\/a>\n\t\n\t\t\t<\/span>\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\n\t\t\t\n\t\n\tMagnus Gustafsson, Head of Global Business Development at Biovian<\/span>\n\n\t\t\t<\/a>\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n<\/div>\n<\/div>\n\t\t\t
\n\t
\n\t
\n\t\t
\n\t\n\t\n\tDay 2 | 10:00<\/span>\n\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\t\t<\/span>\n\t\n\t\t\t\n\t\n\tAseptic bag processing: bridging the gap<\/span>\n\n\t\t\t<\/a>\n\t\n\t\t\t<\/span>\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\n\t\t\t\n\t\n\tChristian Kollecker, Business Unit Leader Pharma Liquid \/ Aseptic at Harro H\u00f6fliger<\/span>\n\n\t\t\t<\/a>\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n<\/div>\n<\/div>\n\t<\/div>\n\t\t<\/div>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t\t\t\t\t
\n\t\t\n
\n\t\t\t
\n\t
\n\t
\n\t\t
\n\t\n\t\n\tDay 1 | 11:00<\/span>\n\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\t\t<\/span>\n\t\n\t\t\t\n\t\n\tLearn How to Trend & Analyze Environmental Monitoring Data<\/span>\n\n\t\t\t<\/a>\n\t\n\t\t\t<\/span>\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\n\t\t\t\n\t\n\tSusan Cleary, Director of Product Development at Novatek International<\/span>\n\n\t\t\t<\/a>\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n<\/div>\n<\/div>\n\t\t\t
\n\t
\n\t
\n\t\t
\n\t\n\t\n\tDay 2 | 11:00<\/span>\n\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\t\t<\/span>\n\t\n\t\t\t\n\t\n\tUse of Robotics in Flexible Format Aseptic Filling<\/span>\n\n\t\t\t<\/a>\n\t\n\t\t\t<\/span>\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\n\t\t\t\n\t\n\tKeith W. Dodson, Vice President of Business Development at AST (Automated Systems of Tacoma)<\/span>\n\n\t\t\t<\/a>\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n<\/div>\n<\/div>\n\t<\/div>\n\t\t<\/div>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t\t\t\t\t
\n\t\t\n
\n\t\t\t
\n\t
\n\t
\n\t\t
\n\t\n\t\n\tDay 1 | 12:00<\/span>\n\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\t\t<\/span>\n\t\n\t\t\t\n\t\n\tContamination and Cross Contamination Control during Aseptic Manufacturing<\/span>\n\n\t\t\t<\/a>\n\t\n\t\t\t<\/span>\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\n\t\t\t\n\t\n\tRichard Denk, Senior Consultant Aseptic Processing & Containment at SKAN AG<\/span>\n\n\t\t\t<\/a>\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n<\/div>\n<\/div>\n\t\t\t
\n\t
\n\t
\n\t\t
\n\t\n\t\n\tDay 2 | 12:00<\/span>\n\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\t\t<\/span>\n\t\n\t\t\t\n\t\n\tConcept and Implementation of a Global Contamination Control Strategy<\/span>\n\n\t\t\t<\/a>\n\t\n\t\t\t<\/span>\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\n\t\t\t\n\t\n\tChristoph Hansy, Global Microbiology Management at Takeda<\/span>\n\n\t\t\t<\/a>\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n<\/div>\n<\/div>\n\t<\/div>\n\t\t<\/div>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t\t\t\t\t
\n\t\t\n
\n\t\t\t
\n\t
\n\t
\n\t\t
\n\t\n\t\n\tDay 1 | 13:00<\/span>\n\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\t\t<\/span>\n\t\n\t\t\t\n\t\n\tInnovative and Agile Approaches in the Aseptic Manufacturing of Lyophilised Vialed Drug Products<\/span>\n\n\t\t\t<\/a>\n\t\n\t\t\t<\/span>\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\n\t\t\t\n\t\n\tDr. Thomas Becker, Director Site Quality at Recipharm<\/span>\n\n\t\t\t<\/a>\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n<\/div>\n<\/div>\n\t\t\t
\n\t
\n\t
\n\t\t
\n\t\n\t\n\tDay 2 | 13:00<\/span>\n\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\t\t<\/span>\n\t\n\t\t\t\n\t\n\tContamination Control Strategy, an Implementation approach.<\/span>\n\n\t\t\t<\/a>\n\t\n\t\t\t<\/span>\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\n\t\t\t\n\t\n\tWalid El Azab, Senior Manager Technical Service at STERIS<\/span>\n\n\t\t\t<\/a>\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n<\/div>\n<\/div>\n\t<\/div>\n\t\t<\/div>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t\t\t\t\t
\n\t\t\n
\n\t\t\t
\n\t
\n\t
\n\t\t
\n\t\n\t\n\tDay 1 | 14:00<\/span>\n\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\t\t<\/span>\n\t\n\t\t\t\n\t\n\tCombined ATMP Viral vector formulation and filling on an integrated Barrier technology platform<\/span>\n\n\t\t\t<\/a>\n\t\n\t\t\t<\/span>\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\n\t\t\t\n\t\n\tJames L. Drinkwater, Head of GMP compliance & Aseptic process integration F Ziel GbmH<\/span>\n\n\t\t\t<\/a>\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n<\/div>\n<\/div>\n\t\t\t
\n\t
\n\t
\n\t\t
\n\t\n\t\n\tDay 2 | 14:00<\/span>\n\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\t\t<\/span>\n\t\n\t\t\t\n\t\n\tTrends in Manufacturing Dry Vaccine Product<\/span>\n\n\t\t\t<\/a>\n\t\n\t\t\t<\/span>\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\n\t\t\t\n\t\n\tSue Behrens, Professor in Bioprocessing and Director, Amgen Bioprocessing Center at Keck Graduate Institute<\/span>\n\n\t\t\t<\/a>\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n<\/div>\n<\/div>\n\t<\/div>\n\t\t<\/div>\n\t<\/div>\n<\/div>\n<\/div>\t\t\t\n\t\t\t\t
\n\t
\n\t\t\t\t\t\t
\n\t\t\n
\n\t\t\t
\n\t
\n\t
\n\t\t

\n\t\t\t<\/span>\n\t\n\t\n\tDay 1<\/span>\n\n\t\n\t\t\t<\/span>\n\t<\/h3>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t

\n\t\t\t<\/span>\n\t\n\t\n\tBiobanking (Part I)<\/span>\n\n\t\n\t\t\t<\/span>\n\t<\/h4>\n\t<\/div>\n<\/div>\n<\/div>\n<\/div>\n\t\t\t
\n\t
\n\t
\n\t\t

\n\t\t\t<\/span>\n\t\n\t\n\tDay 2<\/span>\n\n\t\n\t\t\t<\/span>\n\t<\/h3>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t

\n\t\t\t<\/span>\n\t\n\t\n\tCDx & Biomarkers (Part II)<\/span>\n\n\t\n\t\t\t<\/span>\n\t<\/h4>\n\t<\/div>\n<\/div>\n<\/div>\n<\/div>\n\t<\/div>\n\n
\n\t\t\t
\n\t
\n\t
\n\t\t
\n\t\n\t\n\tDay 1 | 09:00<\/span>\n\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\t\t<\/span>\n\t\n\t\t\t\n\t\n\tBiobanking During the COVID-19 Pandemic<\/span>\n\n\t\t\t<\/a>\n\t\n\t\t\t<\/span>\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\n\t\t\t\n\t\n\tJim Vaught, Ph.D. Editor-in-Chief, Biopreservation & Biobanking<\/span>\n\n\t\t\t<\/a>\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n<\/div>\n<\/div>\n\t\t\t
\n\t
\n\t
\n\t\t
\n\t\n\t\n\tDay 2 | 09:00<\/span>\n\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\t\t<\/span>\n\t\n\t\t\t\n\t\n\tOvercoming the challenges of RNASeq with extraction-free, low sample input gene expression profiling by the HTG Transcriptome Panel<\/span>\n\n\t\t\t<\/a>\n\t\n\t\t\t<\/span>\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\n\t\t\t\n\t\n\tSelina Gaertner, Medical Affairs Manager EMEA at HTG Molecular Diagnostics<\/span>\n\n\t\t\t<\/a>\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n<\/div>\n<\/div>\n\t<\/div>\n\t\t<\/div>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t\t\t\t\t
\n\t\t\n
\n\t\t\t
\n\t
\n\t
\n\t\t
\n\t\n\t\n\tDay 1 | 10:00<\/span>\n\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\t\t<\/span>\n\t\n\t\t\t\n\t\n\tEpigenetic biomarkers for Type 2 Diabetes from plasma - and saliva derived extracellular vesicles<\/span>\n\n\t\t\t<\/a>\n\t\n\t\t\t<\/span>\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\n\t\t\t\n\t\n\tDr. Christa Noehammer, Senior Scientist at AIT (Austrian Institute of Technology)<\/span>\n\n\t\t\t<\/a>\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n<\/div>\n<\/div>\n\t\t\t
\n\t
\n\t
\n\t\t
\n\t\n\t\n\tDay 2 | 10:00<\/span>\n\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\t\t<\/span>\n\t\n\t\t\t\n\t\n\tMolecular Characterization of CTCs in ALK-rearranged Non-Small-Cell Lung Cancer resistant to ALK inhibitors<\/span>\n\n\t\t\t<\/a>\n\t\n\t\t\t<\/span>\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\n\t\t\t\n\t\n\tMarianne Oulhen Head of Projects at Gustave Roussy<\/span>\n\n\t\t\t<\/a>\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n<\/div>\n<\/div>\n\t<\/div>\n\t\t<\/div>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t\t\t\t\t
\n\t\t\n
\n\t\t\t
\n\t
\n\t
\n\t\t
\n\t\n\t\n\tDay 1 | 11:00<\/span>\n\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\t\t<\/span>\n\t\n\t\t\t\n\t\n\tFrom Biobanking to Personal medicine and Prevention<\/span>\n\n\t\t\t<\/a>\n\t\n\t\t\t<\/span>\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\n\t\t\t\n\t\n\tProf. Andres Metspalu, Professor at University of Tartu<\/span>\n\n\t\t\t<\/a>\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n<\/div>\n<\/div>\n\t\t\t
\n\t
\n\t
\n\t\t
\n\t\n\t\n\tDay 2 | 11:00<\/span>\n\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\t\t<\/span>\n\t\n\t\t\t\n\t\n\tCurrent challenges of liquid biopsy research<\/span>\n\n\t\t\t<\/a>\n\t\n\t\t\t<\/span>\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\n\t\t\t\n\t\n\tKlaus Pantel, Chairman of the Institute of Tumour Biology at the University Medical Center Hamburg-Eppendorf.<\/span>\n\n\t\t\t<\/a>\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n<\/div>\n<\/div>\n\t<\/div>\n\t\t<\/div>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t\t\t\t\t
\n\t\t\n
\n\t\t\t
\n\t
\n\t
\n\t\t
\n\t\n\t\n\tDay 1 | 12:00<\/span>\n\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\t\t<\/span>\n\t\n\t\t\t\n\t\n\tModern Biobanking - Critical Success Factors and future considerations. <\/span>\n\n\t\t\t<\/a>\n\t\n\t\t\t<\/span>\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\n\t\t\t\n\t\n\tKarine Sargsyan, Chief Operating Officer at Biobank Graz<\/span>\n\n\t\t\t<\/a>\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n<\/div>\n<\/div>\n\t\t\t
\n\t
\n\t
\n\t\t
\n\t\n\t\n\tDay 2 | 12:00<\/span>\n\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\t\t<\/span>\n\t\n\t\t\t\n\t\n\tLiquid Biopsy: From Discovery to Clinical Application<\/span>\n\n\t\t\t<\/a>\n\t\n\t\t\t<\/span>\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\n\t\t\t\n\t\n\tDr. Catherine Alix-Panabi\u00e8res, Director LCCRH at the University Medical Center of Montpellier<\/span>\n\n\t\t\t<\/a>\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n<\/div>\n<\/div>\n\t<\/div>\n\t\t<\/div>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t\t\t\t\t
\n\t\t\n
\n\t\t\t
\n\t
\n\t
\n\t\t
\n\t\n\t\n\tDay 1 | 13:00<\/span>\n\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\t\t<\/span>\n\t\n\t\t\t\n\t\n\tBBMRI-ERIC partnering to support Research and Development for improved Precision Medicine<\/span>\n\n\t\t\t<\/a>\n\t\n\t\t\t<\/span>\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\n\t\t\t\n\t\n\tProfessor Jens K. Habermann, Director General at BBMRI-ERIC<\/span>\n\n\t\t\t<\/a>\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n<\/div>\n<\/div>\n\t\t\t
\n\t
\n\t
\n\t\t
\n\t\n\t\n\tDay 2 | 13:00<\/span>\n\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\t\t<\/span>\n\t\n\t\t\t\n\t\n\tCommercialization of companion diagnostics<\/span>\n\n\t\t\t<\/a>\n\t\n\t\t\t<\/span>\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\n\t\t\t\n\t\n\tDr. Reinhard Ortmann, Director Companion Diagnostics at QIAGEN<\/span>\n\n\t\t\t<\/a>\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n<\/div>\n<\/div>\n\t<\/div>\n\t\t<\/div>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t\t\t\t\t
\n\t\t\n
\n\t\t\t
\n\t
\n\t
\n\t\t
\n\t\n\t\n\tDay 1 | 14:00<\/span>\n\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\t\t<\/span>\n\t\n\t\t\t\n\t\n\tTowards returning actionable genetic research results to biobank participants<\/span>\n\n\t\t\t<\/a>\n\t\n\t\t\t<\/span>\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\n\t\t\t\n\t\n\tShona Kerr, Project Manager at MRC Human Genetics Unit, Edinburgh<\/span>\n\n\t\t\t<\/a>\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n<\/div>\n<\/div>\n\t\t\t
\n\t
\n\t
\n\t\t
\n\t\n\t\n\tDay 2 | 14:00<\/span>\n\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\t\t<\/span>\n\t\n\t\t\t\n\t\n\tClinical applications of liquid biopsies<\/span>\n\n\t\t\t<\/a>\n\t\n\t\t\t<\/span>\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\n\t\t\t\n\t\n\tChristian Werno, Research group leader at Fraunhofer Institute<\/span>\n\n\t\t\t<\/a>\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n<\/div>\n<\/div>\n\t<\/div>\n\t\t<\/div>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t\t\t\t\t
\n\t\t\n
\n\t\t\t
\n\t
\n\t
\n\t\t

\n\t\t\t<\/span>\n\t\n\t\n\tCDx & Biomarkers (Part I)<\/span>\n\n\t\n\t\t\t<\/span>\n\t<\/h4>\n\t<\/div>\n<\/div>\n<\/div>\n<\/div>\n\t\t\t
\n\t
\n\t
\n\t\t

\n\t\t\t<\/span>\n\t\n\t\n\tBiobanking (Part II)<\/span>\n\n\t\n\t\t\t<\/span>\n\t<\/h4>\n\t<\/div>\n<\/div>\n<\/div>\n<\/div>\n\t<\/div>\n\t\t<\/div>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t\t\t\t\t
\n\t\t\n
\n\t\t\t
\n\t
\n\t
\n\t\t
\n\t\n\t\n\tDay 1 | 15:00<\/span>\n\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\t\t<\/span>\n\t\n\t\t\t\n\t\n\tCirculating biomarkers for cancer diagnosis and precision medicine<\/span>\n\n\t\t\t<\/a>\n\t\n\t\t\t<\/span>\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\n\t\t\t\n\t\n\tYong-Jie Lu MD, PhD Professor in Molecular Oncology at Queen Mary University of London<\/span>\n\n\t\t\t<\/a>\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n<\/div>\n<\/div>\n\t\t\t
\n\t
\n\t
\n\t\t
\n\t\n\t\n\tDay 2 | 15:00<\/span>\n\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\t\t<\/span>\n\t\n\t\t\t\n\t\n\tBiobanking of spheroids\/organoids\/tumoroids<\/span>\n\n\t\t\t<\/a>\n\t\n\t\t\t<\/span>\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\n\t\t\t\n\t\n\tIda Biunno, Professor at Biomedicine at the University of Milano<\/span>\n\n\t\t\t<\/a>\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n<\/div>\n<\/div>\n\t<\/div>\n\t\t<\/div>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t\t\t\t\t
\n\t\t\n
\n\t\t\t
\n\t
\n\t
\n\t\t
\n\t\n\t\n\tDay 1 | 16:00<\/span>\n\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\t\t<\/span>\n\t\n\t\t\t\n\t\n\tBiomarkers in pathology and radiology<\/span>\n\n\t\t\t<\/a>\n\t\n\t\t\t<\/span>\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\n\t\t\t\n\t\n\tCarla Leibowitz, Chief BD Officer at Paige.AI<\/span>\n\n\t\t\t<\/a>\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n<\/div>\n<\/div>\n\t\t\t
\n\t
\n\t
\n\t\t
\n\t\n\t\n\tDay 2 | 16:00<\/span>\n\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\t\t<\/span>\n\t\n\t\t\t\n\t\n\tBiobank - an overview<\/span>\n\n\t\t\t<\/a>\n\t\n\t\t\t<\/span>\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\n\t\t\t\n\t\n\tIng. Pasquale De Blasio, Founder & CEO of Integrated Systems Engineering (ISENET)<\/span>\n\n\t\t\t<\/a>\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n<\/div>\n<\/div>\n\t<\/div>\n\t\t<\/div>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t\t\t\t\t
\n\t\t\n
\n\t\t\t
\n\t
\n\t
\n\t\t
\n\t\n\t\n\tDay 1 | 17:00<\/span>\n\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\t\t<\/span>\n\t\n\t\t\t\n\t\n\tRegulatory-scientific challenges for predictive biomarker based personalized medicines<\/span>\n\n\t\t\t<\/a>\n\t\n\t\t\t<\/span>\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\n\t\t\t\n\t\n\tDr. J\u00f6rg Engelbergs, Scientific-Regulatory Expert at Paul-Ehrlich-Institut & European Medicines Agency<\/span>\n\n\t\t\t<\/a>\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n<\/div>\n<\/div>\n\t\t\t
\n\t
\n\t
\n\t\t
\n\t\n\t\n\tDay 2 | 17:00<\/span>\n\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\t\t<\/span>\n\t\n\t\t\t\n\t\n\tAll about the qualification in Biorepository Science (QBRS)<\/span>\n\n\t\t\t<\/a>\n\t\n\t\t\t<\/span>\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\n\t\t\t\n\t\n\tBrent Schacter, MD FRCPC FCAHS Professor Emeritus at Rady College of Medicine, University of Manitoba<\/span>\n\n\t\t\t<\/a>\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n<\/div>\n<\/div>\n\t<\/div>\n\t\t<\/div>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t\t\t\t\t
\n\t\t\n
\n\t\t\t
\n\t
\n\t
\n\t\t
\n\t\n\t\n\tDay 1 | 18:00<\/span>\n\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\t\t<\/span>\n\t\n\t\t\t\n\t\n\tNeed for workflow solutions from sample collection to diagnostic assay<\/span>\n\n\t\t\t<\/a>\n\t\n\t\t\t<\/span>\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\n\t\t\t\n\t\n\tDaniel Gr\u00f6lz, Scientific Associate Director R&D, Sample Technologies Department at QIAGEN<\/span>\n\n\t\t\t<\/a>\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n<\/div>\n<\/div>\n\t\t\t
\n\t
\n\t
\n\t\t
\n\t\n\t\n\tDay 2 | 18:00<\/span>\n\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\t\t<\/span>\n\t\n\t\t\t\n\t\n\tBuilding a GMP Biobanking Network in Europe<\/span>\n\n\t\t\t<\/a>\n\t\n\t\t\t<\/span>\n\t<\/h5>\n\t<\/div>\n<\/div>\n
\n\t
\n\t\t
\n\t\n\t\t\t\n\t\n\tDr. Vincent von Walcke-Wulffen, CEO at BioKryo GmbH<\/span>\n\n\t\t\t<\/a>\n\t\n\t<\/h5>\n\t<\/div>\n<\/div>\n<\/div>\n<\/div>\n\t<\/div>\n\t\t<\/div>\n\t<\/div>\n<\/div>\n<\/div>\t\t\t\n\n<\/div>","protected":false},"excerpt":{"rendered":"

Download now the Official In-Person Agenda Click here to download the agenda Agenda for the Virtual Format of the conference Please note: The agenda below is only for the virtual format. 1. Antibody Engineering & Therapeutics 2. Inhalation & Respiratory Drug Delivery 3. Pharmacovigilance & Drug Safety 4. Pre-filled Syringes & Injectables 5. Gut-Brain Axis…<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"inline_featured_image":false,"footnotes":""},"class_list":["post-15558","page","type-page","status-publish","hentry"],"yoast_head":"\nAgenda • BioTech Pharma Summit<\/title>\n<meta name=\"description\" content=\"The 2nd Annual IRDD Summit 2020 will focus on the challenges of bringing respiratory products to market and innovative aerosol science.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.biotechpharmasummit.com\/index.php\/agenda\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Agenda - IRDD Summit 2020\" \/>\n<meta property=\"og:description\" content=\"The 2nd Annual IRDD Summit 2020 will focus on the challenges of bringing respiratory products to market and innovative aerosol science.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.biotechpharmasummit.com\/index.php\/agenda\/\" \/>\n<meta property=\"og:site_name\" content=\"BioTech Pharma Summit\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/biotechpharmasummit\/\" \/>\n<meta property=\"article:modified_time\" content=\"2021-11-25T22:09:00+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:title\" content=\"Agenda - IRDD Summit 2020\" \/>\n<meta name=\"twitter:description\" content=\"The 2nd Annual IRDD Summit 2020 will focus on the challenges of bringing respiratory products to market and innovative aerosol science.\" \/>\n<meta name=\"twitter:site\" content=\"@biotechsummit\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/agenda\/\",\"url\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/agenda\/\",\"name\":\"Agenda • BioTech Pharma Summit\",\"isPartOf\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#website\"},\"datePublished\":\"2018-05-28T18:09:41+00:00\",\"dateModified\":\"2021-11-25T22:09:00+00:00\",\"description\":\"The 2nd Annual IRDD Summit 2020 will focus on the challenges of bringing respiratory products to market and innovative aerosol science.\",\"breadcrumb\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/agenda\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.biotechpharmasummit.com\/index.php\/agenda\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/agenda\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.biotechpharmasummit.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Agenda\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#website\",\"url\":\"https:\/\/www.biotechpharmasummit.com\/\",\"name\":\"BioTech Pharma Summit\",\"description\":\"The Tomorrow's healthcare congress\",\"publisher\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.biotechpharmasummit.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#organization\",\"name\":\"EPM Group\",\"url\":\"https:\/\/www.biotechpharmasummit.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/05\/B_2_Logo_BioTech_Pharma_Summit_Porto.png\",\"contentUrl\":\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/05\/B_2_Logo_BioTech_Pharma_Summit_Porto.png\",\"width\":2000,\"height\":2000,\"caption\":\"EPM Group\"},\"image\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/biotechpharmasummit\/\",\"https:\/\/x.com\/biotechsummit\",\"https:\/\/www.instagram.com\/biotechpharmasummit\/\",\"https:\/\/www.linkedin.com\/company\/biotech-pharma-summit\/\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Agenda • BioTech Pharma Summit","description":"The 2nd Annual IRDD Summit 2020 will focus on the challenges of bringing respiratory products to market and innovative aerosol science.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.biotechpharmasummit.com\/index.php\/agenda\/","og_locale":"en_US","og_type":"article","og_title":"Agenda - IRDD Summit 2020","og_description":"The 2nd Annual IRDD Summit 2020 will focus on the challenges of bringing respiratory products to market and innovative aerosol science.","og_url":"https:\/\/www.biotechpharmasummit.com\/index.php\/agenda\/","og_site_name":"BioTech Pharma Summit","article_publisher":"https:\/\/www.facebook.com\/biotechpharmasummit\/","article_modified_time":"2021-11-25T22:09:00+00:00","twitter_card":"summary_large_image","twitter_title":"Agenda - IRDD Summit 2020","twitter_description":"The 2nd Annual IRDD Summit 2020 will focus on the challenges of bringing respiratory products to market and innovative aerosol science.","twitter_site":"@biotechsummit","twitter_misc":{"Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/agenda\/","url":"https:\/\/www.biotechpharmasummit.com\/index.php\/agenda\/","name":"Agenda • BioTech Pharma Summit","isPartOf":{"@id":"https:\/\/www.biotechpharmasummit.com\/#website"},"datePublished":"2018-05-28T18:09:41+00:00","dateModified":"2021-11-25T22:09:00+00:00","description":"The 2nd Annual IRDD Summit 2020 will focus on the challenges of bringing respiratory products to market and innovative aerosol science.","breadcrumb":{"@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/agenda\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.biotechpharmasummit.com\/index.php\/agenda\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/agenda\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.biotechpharmasummit.com\/"},{"@type":"ListItem","position":2,"name":"Agenda"}]},{"@type":"WebSite","@id":"https:\/\/www.biotechpharmasummit.com\/#website","url":"https:\/\/www.biotechpharmasummit.com\/","name":"BioTech Pharma Summit","description":"The Tomorrow's healthcare congress","publisher":{"@id":"https:\/\/www.biotechpharmasummit.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.biotechpharmasummit.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.biotechpharmasummit.com\/#organization","name":"EPM Group","url":"https:\/\/www.biotechpharmasummit.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.biotechpharmasummit.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/05\/B_2_Logo_BioTech_Pharma_Summit_Porto.png","contentUrl":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/05\/B_2_Logo_BioTech_Pharma_Summit_Porto.png","width":2000,"height":2000,"caption":"EPM Group"},"image":{"@id":"https:\/\/www.biotechpharmasummit.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/biotechpharmasummit\/","https:\/\/x.com\/biotechsummit","https:\/\/www.instagram.com\/biotechpharmasummit\/","https:\/\/www.linkedin.com\/company\/biotech-pharma-summit\/"]}]}},"_links":{"self":[{"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/pages\/15558","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/comments?post=15558"}],"version-history":[{"count":40,"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/pages\/15558\/revisions"}],"predecessor-version":[{"id":37252,"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/pages\/15558\/revisions\/37252"}],"wp:attachment":[{"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/media?parent=15558"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}